Type of security: Stock
Sector: Health Care
Industry: Biotechnology: Biological Products (No Diagnostic Substances)
The data is delayed by 15 minutes.
Description: Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, is focused on the discovery, development, and commercialization of first-in-class glaucoma therapies. Its lead product candidate, Rhopressa, is a once-daily triple-action eye drop, which demonstrated the ability to reduce intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension in a Phase 2b clinical trial. The company is conducting two Phase 3 registration trials in the U.S. to demonstrate non-inferiority of IOP lowering for Rhopressa compared to timolol, as well as commencing a third safety-only Phase 3 registration trial of Rhopressa in Canada. It also develops once-daily quadruple-action Roclatan, a single drop combination of Rhopressa with latanoprost, which has completed a 28-day Phase 2b clinical trial. In addition, the company is taking preparatory steps for Phase 3 registration trials for Roclatan. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Bedminster, New Jersey.
|Shares Outstanding||EPS||-3.31||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||Sales Growth - Q/Q||P/E||-15.12|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-30.07%||ROE||-120.74%||ROI|
|Current Ratio||7.63||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.46|
|Gross Margin||Operating Margin||Net Profit Margin||Dividend Payout Ratio|
|Cash From Financing Activities||35.07 M||Cash From Investing Activities||6.1 M||Cash From Operating Activities||-13.31 M||Gross Profit|
|Net Profit||-17.24 M||Operating Profit||-19.64 M||Total Assets||195.2 M||Total Current Assets||170.96 M|
|Total Current Liabilities||22.39 M||Total Debt||124.19 M||Total Liabilities||146.58 M||Total Revenue|
|High 52 week||73.9||Low 52 week||33||Last close||39.06||Last change||-3.65%|
|RSI||49.1||Average true range||2.31||Beta||1.37||Volume||623.98 K|
|Simple moving average 20 days||-1.74%||Simple moving average 50 days||-9.69%||Simple moving average 200 days||-19%|
|Performance Week||-9.21%||Performance Month||-1.81%||Performance Quart||-6.44%||Performance Half||-9.83%|
|Performance Year||-23.71%||Performance Year-to-date||8.2%||Volatility daily||3.7%||Volatility weekly||8.26%|
|Volatility monthly||16.94%||Volatility yearly||58.67%||Relative Volume||235.1%||Average Volume||664.56 K|
|New High||New Low|
2019-06-18 08:05:56 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-13 08:03:28 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-11 08:04:17 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-11 07:30:00 | Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences
2019-06-10 08:05:36 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-06-06 13:58:01 | Does Aerie Pharmaceuticals, Inc. NASDAQ:AERI Have A Particularly Volatile Share Price?
2019-06-06 09:31:01 | Why Is Aerie AERI Down 10.2% Since Last Earnings Report?
2019-06-06 08:06:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-05-28 07:30:00 | Aerie Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference
2019-05-21 17:36:09 | Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
2019-05-08 14:45:06 | Aerie AERI Q1 Earnings Beat, Rhopressa Misses Estimates
2019-05-08 00:02:38 | Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT
2019-05-07 22:46:35 | Aerie Pharmaceuticals, Inc. AERI Q1 2019 Earnings Call Transcript
2019-05-07 18:15:10 | Aerie Pharmaceuticals AERI Reports Q1 Loss, Lags Revenue Estimates
2019-05-07 17:09:37 | Aerie: 1Q Earnings Snapshot
2019-05-07 08:05:55 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-05-03 14:42:30 | Another $100 million 'safety net' set for this Triangle pharma
2019-05-02 12:42:44 | Here’s What Hedge Funds Think About Aerie Pharmaceuticals Inc AERI
2019-05-01 12:00:00 | With profits in sight, Durham pharma launches new trials
2019-04-30 08:05:49 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-04-11 10:05:00 | Aerie and Inovio Among Pharma Stocks Offering High Risk and Even Higher Upside
2019-04-10 12:05:55 | Have Insiders Been Selling Aerie Pharmaceuticals, Inc. NASDAQ:AERI Shares This Year?
2019-04-02 07:30:00 | Aerie Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference
2019-03-28 17:07:09 | Aerie AERI Improves 22% YTD: Is Momentum Likely to Sustain?
2019-03-27 09:30:01 | Aerie AERI Down 2.9% Since Last Earnings Report: Can It Rebound?
2019-03-25 06:30:00 | Aerie Pharmaceuticals Announces Four Appointments
2019-03-22 11:23:03 | Aerie AERI Starts Phase II Study on Eye Candidate in Japan
2019-03-19 12:28:04 | Aerie AERI Starts Phase II Study on Eye Candidate AR-1105
2019-03-13 12:50:04 | Aerie AERI Receives FDA Nod for Rocklatan to Treat Glaucoma
2019-03-12 18:30:00 | Aerie Pharmaceuticals Announces Full-Year 2019 Net Revenue and Net Cash Burn Guidance
2019-03-12 18:20:00 | Aerie Pharmaceuticals Announces U.S. FDA Approval of Rocklatan™ netarsudil and latanoprost ophthalmic solution 0.02%/0.005% for the Reduction of Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension
2019-03-07 08:13:36 | Introducing Aerie Pharmaceuticals, The Stock That Zoomed 271% In The Last Three Years
2019-03-05 08:02:09 | See what the IHS Markit Score report has to say about Aerie Pharmaceuticals Inc.
2019-03-05 07:30:00 | Aerie Pharmaceuticals to Present at Two Investor Conferences in March
2019-03-01 08:25:00 | New Research Coverage Highlights Micron Technology, Varian Medical, St. Joe, Himax Technologies, Aerie Pharmaceuticals, and Hexcel — Consolidated Revenues, Company Growth, and Expectations for 2019
2019-02-26 20:40:37 | Edited Transcript of AERI earnings conference call or presentation 25-Feb-19 10:00pm GMT
2019-02-26 10:34:03 | Aerie AERI Q4 Earnings Miss, Rhopressa Gains Traction
2019-02-25 21:13:52 | Aerie Pharmaceuticals Inc AERI Q4 2018 Earnings Conference Call Transcript
2019-02-22 13:55:45 | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs